\My research is centered around discovery and characterization of biomarkers for screening, diagnosis, and prognosis of cancer, in particular, ovarian and pancreatic cancers. My group has identified biomarker combinations that recognize ovarian cancer 1-4 years earlier than current methods (CA125 and transvaginal ultrasound) and pancreatic cancer – 2-6 years earlier. We are working on discovering biomarkers in several bodily fluids including serum/plasma and urine and in exosomes obtained from these fluids.
In additional, we are investigating the pre-neoplastic microenvironment in high-grade serous ovarian carcinoma, and the role of glycolysis and coagulation pathways in the early preneoplastic events of high-grade serous ovarian carcinoma and the role of exosomes in these events.
- BS, University of Leningrad, 1974
- MS, University of Leningrad, 1977
- PhD, University of Leningrad, 1983
Education & Training
Mirus JE, Zhang Y, Li CL, et al. Cross-species antibody microarray interrogation identifies a 3-protein panel of plasma biomarkers for early diagnosis of pancreas cancer. Cancer Research. 2015; 21: 1764-71.
Nolen, BM, Lomakin A, Marrangoni A, Velikokhatnaya L, Prosser D, Lokshin AE. Urinary protein biomarkers in the early detection of lung cancer. Cancer Prevention Research. 2015; 8: 111-9.
Nolen BM, Brand RE, Prosser D, et al. Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study. PloS one. 2014; 9: e94928.
Nolen BM, Orlichenko LS, Marrangoni A, et al. An extensive targeted proteomic analysis of disease-related protein biomarkers in urine from healthy donors. PloS one. 2013; 8: e63368.
Bigbee WL, Gopalakrishnan V, Weissfeld JL, et al. A multiplexed serum biomarker immunoassay panel discriminates clinical lung cancer patients from high-risk individuals found to be cancer-free by CT screening. Journal of thoracic oncology. Official publications of ther Internaional Association for the Study of Lung Cancer. 2012; 7: 698-708.
Clendenen TV, Lundin E, Zeleniuch-Jacquotte A, et al. Circulating inflammation markers and risk of epithelial ovarian cancer. Cancer epidemiology, biomarkers & prevention :. American Association for Cancer Research. 2011; 20: 799-810.
Al Efishat, M.A., Attiyeh, M.F., Eaton, A.A., Gönen, M., Prosser, D., Lokshin, A.E., Castillo, C.F., Lillemoe K,D., Ferrone, C.R., Pergolini, I., Mino-Kenudson, M., Rezaee, N., Dal Molin, M., Weiss, M.J., Cameron, J.L., Hruban, R.H., D'Angelica, M.I., Jarnagin, W.R., Wolfgang, C.L., Allen, P.J. Multi-Institutional Validation Study of Pancreatic Cyst Fluid Protein Analysis for Prediction of High-Risk Intraductal Papillary Mucinous Neoplasms of the Pancreas. Annals of Surgery. 2017
Shurin, M.R., Ma, Y., Keskinov, A.A., Zhao, R., Lokshin, A., Agassandian, M., Shurin, G.V. BAFF and APRIL from Activin A-Treated Dendritic Cells Upregulate the Antitumor Efficacy of Dendritic Cells In Vivo. Cancer Research. 2016; 76: 4959-69.
Kim, S.H., Hahm, E.R., Arlotti, J.A., Samanta, S.K., Moura, M.B., Thorne, S.H., Shuai, Y., Anderson, C.J., White, A.G., Lokshin, A., Lee, J., Singh, S.V. Withaferin A inhibits in vivo growth of breast cancer cells accelerated by Notch2 knockdown. Breast Cancer Research. 2016; 157: 41-54.
- Associate Editor, Cancer Biomarkers, 2004-present
- Member, Ad Hoc Review Team; STTR/SBIR, U01,Omnibus, 2006-present
- Member Oncology 2 - Translational Clinical (OTC) NIH study section, 2017-present
- Associate Editor, Cancers, 2018-present
